| Metric | Current | Prior | YoY |
|---|---|---|---|
| Revenue | ¥159.0B | ¥130.0B | +22.3% |
| Operating Income | ¥27.9B | ¥12.5B | +122.4% |
| Ordinary Income | ¥26.5B | ¥13.8B | +92.8% |
| Net Income | ¥3.2B | ¥9.9B | -67.2% |
| ROE | 0.7% | 2.1% | - |
FY2026 Q1 results: Revenue 159.0B yen (YoY +22.3%), Operating Income 27.9B yen (YoY +122.4%), Ordinary Income 26.5B yen (YoY +92.8%), Net Income 3.2B yen (YoY -67.2%). The quarter demonstrated robust top-line expansion and significant operating profit improvement, with operating margin reaching approximately 17.5% compared to 9.6% in the prior year period. However, extraordinary losses of 24.6B yen primarily from impairment of investment securities substantially reduced net income despite strong operational performance. Full-year forecast projects revenue of 592.5B yen (+14.7% YoY), operating income of 61.2B yen (+22.6% YoY), and net income of 22.4B yen.
[Profitability] Operating margin 17.5% (improved from 9.6% YoY), gross profit margin 42.9%, net profit margin 2.0% (declined from 7.6% YoY due to extraordinary losses). ROE 0.7% based on quarterly net income, substantially below the historical trend. EBIT margin of 17.5% indicates strong operational efficiency, but the compression from operating income to net income reflects material impact from non-recurring items. [Cash Quality] Cash and deposits 33.9B yen (declined 53.2% YoY), short-term debt coverage ratio 0.22x warrants monitoring for liquidity stress. Working capital items show trade receivables increased 35.1% to 199.2B yen, exceeding revenue growth rate and suggesting collection延 challenges. [Investment Efficiency] Total asset turnover 0.167, ROIC estimated at 4.2%. [Financial Health] Equity ratio 50.4% (improved from 50.2% YoY), current ratio 156.9%, quick ratio 136.8%, debt-to-equity ratio 0.98x. Short-term liabilities account for 69.2% of total liabilities, presenting refinancing considerations. Interest-bearing debt totals 225.3B yen with interest coverage ratio of 33.2x based on operating income.
Cash and deposits decreased 38.5B yen YoY to 33.9B yen, representing a 53.2% contraction that significantly constrains liquidity position. The decline occurred alongside operating profit expansion, indicating substantial cash absorption in working capital and non-operating activities. Trade receivables expanded 51.7B yen to 199.2B yen, outpacing revenue growth and suggesting deterioration in collection cycles. Inventory levels remained elevated while trade payables increased 22.5B yen to 68.2B yen, reflecting extended payment terms that partially offset working capital demands. Investment securities declined 17.4B yen to 33.6B yen, consistent with the extraordinary impairment loss recognition. Short-term borrowings of 156.0B yen combined with diminished cash reserves result in a coverage ratio of 0.22x, indicating dependency on credit facility renewals. The combination of cash depletion, working capital expansion, and high short-term debt concentration creates material refinancing and liquidity considerations requiring close monitoring.
Ordinary income of 26.5B yen compared to operating income of 27.9B yen reflects a net non-operating expense of approximately 1.4B yen, primarily comprising financial costs. The extraordinary loss section recorded 24.6B yen, substantially attributed to impairment of investment securities, which depressed income before taxes to 2.0B yen from 26.5B yen at the ordinary income level. This extraordinary item represents 15.5% of quarterly revenue and constitutes a non-recurring element that should be excluded when assessing sustainable earning power. Operating income growth of 122.4% demonstrates strong operational leverage, with SG&A expenses of 40.3B yen growing more slowly than gross profit expansion. However, the quality of earnings faces headwinds from working capital dynamics, as trade receivables growth of 35.1% significantly exceeds revenue growth of 22.3%, indicating potential cash realization delays. The sharp contraction in cash despite operating income doubling suggests that accrual-based profits are not translating to proportional cash generation, warranting attention to Days Sales Outstanding and inventory turnover metrics.
Liquidity and Refinancing Risk: Cash-to-short-term debt ratio of 0.22x combined with 156.0B yen in short-term borrowings creates material refinancing dependency. Cash reserves decreased 53.2% YoY while short-term liabilities comprise 69.2% of total debt, requiring successful credit facility renewals and working capital optimization to maintain financial flexibility.
Working Capital Efficiency Deterioration: Trade receivables increased 35.1% versus revenue growth of 22.3%, indicating collection cycle延. Combined with elevated inventory levels, this expansion absorbs cash and pressures operating cash flow generation despite operating profit improvement.
Investment Securities Valuation Risk: Recognition of 24.6B yen impairment loss in Q1 demonstrates exposure to market value fluctuations in the investment portfolio. Remaining investment securities of 33.6B yen (down 34.1% from prior year) may face additional valuation pressure depending on market conditions and portfolio composition.
[Industry Position] (Reference - Proprietary Analysis)
The company demonstrates a mixed competitive position within the pharmaceutical industry. Operating margin of 17.5% represents strong operational efficiency, supported by 122.4% year-over-year growth in operating income that reflects successful cost management and revenue scale benefits. Revenue growth of 22.3% substantially exceeds typical pharmaceutical industry organic growth rates, indicating market share gains or product cycle strength. However, net profit margin of 2.0% falls significantly below historical company performance of 7.6% and typical pharmaceutical industry profitability due to the extraordinary impairment charge. ROE of 0.7% on a quarterly basis is substantially depressed by the non-recurring loss and represents a considerable distance from pharmaceutical industry median ROE levels typically in the mid-to-high single digits. The equity ratio of 50.4% aligns with conservative pharmaceutical industry capital structures, though liquidity metrics warrant attention relative to industry peers who typically maintain higher cash-to-short-term-debt ratios. The company's asset turnover of 0.167 reflects the asset-intensive nature of pharmaceutical operations, consistent with industry characteristics of high working capital and fixed asset requirements.
※ Industry: Pharmaceutical Manufacturing, Comparison: Historical periods and general industry characteristics, Source: Proprietary analysis
Operational Performance Improvement Masked by Non-Recurring Items: The quarter demonstrates substantial operational progress with operating income more than doubling year-over-year and operating margin expanding to 17.5%. This improvement in core business profitability indicates successful execution of business strategies, though the sustainability of this margin level requires monitoring across subsequent quarters to distinguish cyclical from structural improvements.
Critical Focus Required on Cash Conversion and Liquidity Management: Despite operating income strength, cash reserves contracted 53.2% while working capital expanded, creating a significant gap between accrual profits and cash generation. The cash-to-short-term-debt ratio of 0.22x and short-term liability concentration of 69.2% necessitate immediate attention to Days Sales Outstanding reduction, inventory optimization, and refinancing arrangements to ensure financial flexibility.
Dividend Sustainability Requires Scrutiny: The indicated annual dividend of 45.5 yen per share against Q1 EPS of 13.28 yen produces an exceptionally elevated implied payout ratio. Dividend sustainability depends on achievement of full-year net income guidance of 22.4B yen and successful cash flow generation, requiring investors to monitor quarterly profit trajectory and free cash flow development closely.
This report was automatically generated by AI analyzing XBRL earnings data as an earnings analysis tool. This is not a recommendation to invest in any specific security. Industry benchmarks are reference information compiled from publicly available earnings data. Please make investment decisions at your own responsibility and consult professionals as needed.